[{"orgOrder":0,"company":"OrsoBio","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ OrsoBio"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Longitude Capital","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Longitude Capital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Mitobridge","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Acquisition","leadProduct":"TLC-065","moa":"ACMSD","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ OrsoBio","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ OrsoBio"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Ascenta Capital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Samsara BioCapital","highestDevelopmentStatusID":"5","companyTruncated":"OrsoBio \/ Samsara BioCapital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Phenex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ OrsoBio"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Undisclosed","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"TLC-1235","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ Yale University"}]

Find Clinical Drug Pipeline Developments & Deals by OrsoBio

OrsoBio
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

02

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

03

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

04

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

05

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

06

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

07

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

08

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

09

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

10

OrsoBio

U.S.A

AIChE Annual Meeting

Not Confirmed

1
2